ShanghaiApril 27, 2026 /PRNewswire/ — On April 25, 2026, the Third High-Quality Development Conference of Medical Aesthetics of the China Food and Drug Safety Promotion Association was held in Chengdu. The Group Standard for “Evaluation Methods for Improving Skin Texture and Complexion Using Injectable Tissue-Derived Collagen” (hereinafter referred to as the Group Standard) was officially released at the conference, with implementation set for April 26.
Proposed by Ferman (Changchun) Medical Biotechnology Co., Ltd., and supervised by the China Food and Drug Enterprise Quality and Safety Promotion Association, this standard was jointly drafted by multiple institutions and organizations. It is China’s first specialized group standard for evaluating skin texture and complexion using injectable tissue-derived collagen, filling an industry gap and marking a shift in China’s collagen medical aesthetics from “experience-driven” to “evidence-based standardized” practices.
At the release event, Professor Luo Shengkang from the Department of Plastic and Aesthetic Surgery at Guangdong Second Provincial General Hospital provided an in-depth interpretation of the Group Standard’s core content. He focused on breaking down the dual-dimension evaluation system of “subjective scales + objective testing,” the full-process operational specifications, and the risk prevention strategies within the safety management framework.
The interpretation, enriched with extensive clinical cases, offered practical guidance directly applicable for doctors and institutions, ensuring the effective implementation of the Group Standard in clinical and market settings, and driving its transition from a “document” to “industry action.”
Following the interpretation of the Group Standard, Dr. Liu Qingmei from the Department of Dermatology at Huashan Hospital, Fudan University, delivered a thematic presentation titled “Research on the Structure and Functional Mechanisms of Bovine Active Collagen.” This study, jointly conducted by Fudan University and Ferman Biotechnology, provided solid theoretical support for the Group Standard from a scientific perspective.
The research confirmed that active bovine collagen, primarily composed of Type I and Type III collagen, retains an intact triple-helix structure, exhibits excellent thermal stability, and boasts high biological activity. Its mechanism of action is clear, involving coordinated regulation through multiple signaling pathways to effectively activate skin fibroblasts and promote extracellular matrix remodeling.
Both animal experiments and clinical observations demonstrated that active bovine collagen can achieve immediate filling, nutritional regeneration, and whitening with melanin inhibition in medical aesthetics. In skin applications, it significantly enhances skin hydration, strengthens the skin barrier function, increases dermal thickness and density, and improves skin elasticity. It holds clear clinical value in scenarios such as skin texture optimization and post-photoelectric procedure recovery.
After the presentation, a grand unveiling ceremony was held. Guests including President Mao Zhenbin of the China Food and Drug Enterprise Quality and Safety Promotion Association (former Director of the Inspection Bureau of the former State Food and Drug Administration), Professor Yu Xinhua (Chairman of the National Technical Committee on Quality Management and General Requirements for Medical Devices of Standardization Administration of China, SAC/TC221), Professor Luo Shengkang from Guangdong Second Provincial General Hospital, Professor Zhao Hongyi (Director of the Plastic Surgery Department at Beijing Hospital National Center of Gerontology), Professor Wang Lin (Director of the Plastic and Aesthetic Surgery Department at Dalian University of Technology Affiliated Central Hospital), Dr. Hong Weijin (Head of the Minimally Invasive Team at Guangdong Second Provincial General Hospital), Dr. Liu Qingmei (Associate Researcher at Huashan Hospital, Fudan University), Mr. Chen Xinwei (Managing Director of Ferman Biotechnology), Ms. Zhao Qing (Deputy Managing Director), and Dr. Li Hongqiang (Director of Medical and R&D) jointly took the stage to initiate the unveiling. Over a thousand medical aesthetics industry experts and practitioners witnessed the official release of the Group Standard on-site.
The implementation of this standard achieves multi-party benefits. It sets a benchmark for standardized development in the industry, driving high-quality growth in the collagen medical aesthetics sector. For clinicians, it provides standardized operational and evidence-based evaluation tools, reducing clinical risks while establishing a unified yardstick for academic exchange. For medical aesthetics institutions and managers, the standard serves as a core basis for compliant operations and a key differentiator in competitive markets, effectively empowering front-end conversion and enhancing customer retention and repurchase rates.
From product technology innovation to industry standard setting, Ferman Biotechnology remains steadfast in its industrial responsibility, closely collaborating with industry associations and supply chain partners to continuously promote the standardized and high-quality development of the collagen medical aesthetics industry. Looking ahead, Ferman Biotechnology will take this standard as a new starting point, continuing to provide academic empowerment for clinicians and operational support for partner institutions, working hand-in-hand with all industry peers to build a standardized, healthy, and sustainable medical aesthetics ecosystem.